Bio Usawa Biotechnology
Nairobi, Africa· Est.
African biotech building low‑cost monoclonal antibody biosimilars to expand cancer treatment access.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
African biotech building low‑cost monoclonal antibody biosimilars to expand cancer treatment access.
Oncology
Technology Platform
Cost‑effective manufacturing of monoclonal antibody biosimilars using optimized cell‑culture and purification processes designed for African GMP facilities.
Opportunities
Rapidly expanding African oncology market and the need for affordable biologics create a sizable demand for low‑cost biosimilars produced locally.
Risk Factors
Regulatory approval hurdles, scaling GMP‑compliant manufacturing in Africa, and competition from established global biosimilar manufacturers.
Competitive Landscape
Competes with global biosimilar leaders such as Coherus, Sandoz, and Amgen, but differentiates through local production, cost structure, and focus on African health systems.